ArticleJournal of neuro-oncology2026
Predictors of diagnostic yield and surgical safety in stereotactic brain biopsy.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStereotactic brain biopsy (SBB) is a fundamental diagnostic procedure for intracranial lesions that are radiographically indeterminate or surgically inaccessible. While advances in navigation and perioperative care have enhanced safety, high-granularity data identifying independent predictors of diagnostic failure and complications in large longitudinal cohorts remain limited.
methodsWe retrospectively reviewed 725 adult patients (≥18 years) who underwent SBB at a tertiary academic center between 2014 and 2025. Primary outcomes included diagnostic yield and procedure-related complications, specifically postoperative hemorrhage. A 1:4 nearest-neighbor matched case-control design was used to assess predictors of non-diagnostic yield (n = 184) and postoperative hemorrhage (n = 95), controlling for age and temporal technological changes. Multivariate logistic regression was utilized to calculate odds ratios (OR) and 95% confidence intervals (CI).
resultsThe overall diagnostic yield was 95.0% and the overall complication rate was 4.69%. Multivariate analysis revealed that low-yield pathology (e.g., low-grade glioma, inflammatory, or infectious lesions) was the sole independent predictor of a non-diagnostic result (OR 4.22, 95% CI 1.77–10.06, p = 0.001). Regarding surgical safety, deep-seated location was the only independent predictor of postoperative hemorrhage (OR 3.93, 95% CI 1.24–12.46, p = 0.019). Notably, no statistical differences in yield or safety were observed between robotic, frameless, and frame-based navigation platforms (p > 0.80). Median LOS was 1 day (mean 3.92 ± 5.23 days) and significantly declined over the study period (p = 0.023). Comparative analysis showed that LOS was identical between diagnostic and non-diagnostic groups.
conclusionsOver a decade of institutional experience, SBB demonstrated high diagnostic accuracy and safety across all navigation platforms. These findings identify lesion biology as the primary driver of non-diagnostic sampling and deep-seated location as the chief risk factor for hemorrhage. The comparable hospital resource utilization regardless of diagnostic outcome, combined with a declining LOS, supports the feasibility of standardized early-discharge pathways in modern neuro-oncology. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
41995978What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.